Cost–utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
Nina Gulbrandsen, Finn Wisløff, Erik Nord, Stig Lenhoff, Martin Hjorth, Jan Westin, Nordic Myeloma Study GroupVolume:
66
Year:
2001
Language:
english
Pages:
9
DOI:
10.1034/j.1600-0609.2001.066005328.x
File:
PDF, 101 KB
english, 2001